Inverness buys ischemia test
This article was originally published in The Gray Sheet
Executive Summary
In vitro diagnostic blood test for use with troponin protein tests and electrocardiograms to help rule out heart attacks is acquired by Inverness under a $22.4 mil., all-stock deal to purchase developer Ischemia Technologies. The Ischemia Modified Albumin test was cleared via 510(k) in February 2003. The $30 test addresses a market of roughly 6 mil. patients in the U.S. who present with chest pains at emergency rooms each year. Privately held ITI had 2004 revenue of $1 mil. (1"The Gray Sheet" Feb. 24, 2003, p. 17)...